Jokanovic M, Moretto A, Lotti M
Istituto di Medicina del Lavoro, Università degli Studi di Padova, Italy.
Arch Toxicol. 1998;72(2):93-6. doi: 10.1007/s002040050473.
Certain esterase inhibitors such as O-(2-chloro-2,3,3-trifluorocyclobutyl) O-ethyl S-propyl phosphorothioate (KBR-2822) and phenylmethanesulfonyl fluoride (PMSF) cause exacerbation (promotion) of toxic and traumatic axonopathies. Although these chemicals are capable of inhibiting neuropathy target esterase (NTE), which is the target for organophosphate induced delayed neuropathy, the target for promotion is unlikely to be NTE. Experiments were aimed to ascertain if neuropathy is caused by repeated dosing with a promoter not causing NTE inhibition and in the absence of deliberate injury to axons. Hens were treated with KBR-2822 (0.2 or 0.4 mg/kg per day) by gavage for 90 days and observed for clinical signs up to 21-23 days after treatment when histopathological examination was carried out. NTE and acetylcholinesterase (AChE) were measured at intervals and mean percentages of inhibition at steady state of inhibition/resynthesis (on day 20) were as follows: mean inhibition NTE was < or = 8% in the 0.2 mg/kg group and between 15 and 18% in the 0.4 mg/kg group in brain, spinal cord and peripheral nerve; mean AChE inhibition in brain was 31 and 57% in the two experimental groups, respectively. Controls treated with paraoxon (not neuropathic or a promoter and given at 0.05 mg/kg per day by gavage) showed 45% mean AChE inhibition and no NTE inhibition. Neither clinical nor morphological signs of neuropathy were observed in any group. To ascertain whether subclinical lesions were produced by the repeated treatment with KBR-2822, hens were given KBR-2822 (0.2 mg/kg per day) for 21 days by gavage followed by PMSF (120 mg/kg s.c. 24 h after the last dose of KBR-2822). A control group of hens was treated with the neuropathic DFP (0.03 mg/kg s.c. daily for 21 days causing 40-50% NTE inhibition) followed by PMSF (120 mg/kg s.c.). After PMSF, the KBR-2822 treated hens did not develop neuropathy whereas DFP treated hens did. Lack of neuropathy after repeated treatment with KBR-2822 indicates that a continuous promoting 'pressure' on hen axons is harmless in the absence of a concurrent biochemical or neurotoxic injury.
某些酯酶抑制剂,如O-(2-氯-2,3,3-三氟环丁基)O-乙基S-丙基硫代磷酸酯(KBR-2822)和苯甲基磺酰氟(PMSF),会加重(促进)毒性和创伤性轴索性神经病。尽管这些化学物质能够抑制神经病靶酯酶(NTE),而NTE是有机磷酸酯诱导的迟发性神经病的靶点,但促进作用的靶点不太可能是NTE。实验旨在确定在不抑制NTE且不存在对轴突的蓄意损伤的情况下,重复给予一种促进剂是否会导致神经病。通过灌胃法给母鸡每日服用KBR-2822(0.2或0.4mg/kg),持续90天,并在治疗后长达21-23天观察临床症状,之后进行组织病理学检查。定期测量NTE和乙酰胆碱酯酶(AChE),在抑制/再合成稳态(第20天)时的平均抑制百分比如下:在0.2mg/kg组中,脑、脊髓和周围神经中NTE的平均抑制率≤8%,在0.4mg/kg组中为15%-18%;两个实验组中脑内AChE的平均抑制率分别为31%和57%。用对氧磷(非神经病性或促进剂,通过灌胃法每日给予0.05mg/kg)处理的对照组显示AChE平均抑制率为45%,且无NTE抑制。任何一组均未观察到神经病的临床或形态学体征。为了确定重复用KBR-2822治疗是否会产生亚临床病变,通过灌胃法给母鸡每日服用KBR-2822(0.2mg/kg),持续21天,然后在最后一剂KBR-2822后24小时皮下注射PMSF(120mg/kg)。一组对照母鸡用神经病性的二异丙基氟磷酸酯(DFP,每日皮下注射0.03mg/kg,持续21天,导致40%-50%的NTE抑制)处理,然后皮下注射PMSF(120mg/kg)。给予PMSF后,用KBR-2822处理的母鸡未发生神经病,而用DFP处理的母鸡发生了神经病。重复用KBR-2822治疗后未出现神经病,这表明在没有同时发生的生化或神经毒性损伤的情况下,对母鸡轴突持续施加促进“压力”是无害的。